Sept. 6, 2018 - Today, the latest young-blood medicine-maker, Elevian, emerged from stealth with $5.5 million from investors including Peter Diamandis, one of the more prominent faces in the Silicon Valley “death disruption” scene. Beneath all the hype is some striking science.